ArticleJAMA oncology2023

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.

Alison M Schram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.